UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial

The Lancet (British edition), 2009-08, Vol.374 (9687), p.379-386

2009

Volltextzugriff (PDF)

Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2005-09, Vol.23 (27), p.6674-6681

2005

Volltextzugriff (PDF)

A Multicenter Open-Label Study to Assess the Safety of a New Formulation of BLP25 Liposome Vaccine in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer

Clinical lung cancer, 2010-11, Vol.11 (6), p.391-395

2010

Volltextzugriff (PDF)

Randomized Trial of Amifostine in Locally Advanced Non–Small-Cell Lung Cancer Patients Receiving Chemotherapy and Hyperfractionated Radiation: Radiation Therapy Oncology Group Trial 98-01

Journal of clinical oncology, 2005-04, Vol.23 (10), p.2145-2154

2005

Volltextzugriff (PDF)

The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: Long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801

Lung cancer (Amsterdam, Netherlands), 2013-06, Vol.80 (3), p.298-305

2013

Volltextzugriff (PDF)

Phase II Multicenter Study of Induction Chemotherapy Followed by Concurrent Efaproxiral (RSR13) and Thoracic Radiotherapy for Patients With Locally Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2005-09, Vol.23 (25), p.5918-5928

2005

Volltextzugriff (PDF)

Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy

Cancer chemotherapy and pharmacology, 2011-04, Vol.67 (4), p.837-845

2011

Volltextzugriff (PDF)

Oncologists and family physicians. Using a standardized letter to improve communication

Canadian family physician, 2003-07, Vol.49 (7), p.882-886

2003

Volltextzugriff (PDF)

Consent to Treatment

Lynch, Jane

1, 2010

Volltextzugriff (PDF)

Concurrent weekly carboplatin and radiotherapy for nasopharyngeal carcinoma: report of a joint phase II study

Radiotherapy and oncology, 2001-02, Vol.58 (2), p.131-136

2001

Volltextzugriff (PDF)

PL-4 Phase III study of concurrent chemotherapy and full course radiotherapy (CT/RT) versus CT/RT induction followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): First outcome analysis of North American Intergroup trial 0139 (RTOG 93-09)

Lung cancer (Amsterdam, Netherlands), 2003-08, Vol.41, p.S4-S4

2003

Volltextzugriff (PDF)

Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15)

International journal of radiation oncology, biology, physics, 2002-11, Vol.54 (3), p.719-728

2002

Volltextzugriff (PDF)

Consent to Treatment: Medico-Legal Essentials

1, 2011

Volltextzugriff (PDF)

P3-023: Preliminary results of an escalating dose phase I /II clinical trial of the anti EGFR monoclonal antibody nimotuzumab in combination with external radiotherapy in patients diagnosed with stage IIB, III or IV NSCLC unsuitable for radical therapy

Journal of thoracic oncology, 2007-08, Vol.2 (8), p.S617-S617

2007

Volltextzugriff (PDF)

Radiotherapy plus Chemotherapy with or without Surgical Resection for Stage III Non-Small Cell Lung Cancer

The Lancet (British edition), 2009-07, Vol.374 (9687), p.379-386

2009

Volltextzugriff (PDF)

In Reply

Journal of clinical oncology, 2005-10, Vol.23 (28), p.7233-7235

2005

Volltextzugriff (PDF)

Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 rtog patients

International journal of radiation oncology, biology, physics, 1999-05, Vol.44 (2), p.327-331

1999

Volltextzugriff (PDF)

O-153 Results of a phase II trial of EGF-P64 vaccine in patients with

Lung cancer (Amsterdam, Netherlands), 2003-08, Vol.41, p.S47-S47

2003

Volltextzugriff (PDF)

2147 Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with hyperfractionated radiotherapy with/without chemotherapy: A multivariate analysis of 682 RTOG patients

International journal of radiation oncology, biology, physics, 1997, Vol.39 (2), p.314-314

1997

Volltextzugriff (PDF)

Capacity

Consent to Treatment, 2011, p.151-196

1, 2011

Volltextzugriff (PDF)

Introduction to consent

Consent to Treatment, 2011, p.1-2

1, 2011

Volltextzugriff (PDF)

Custody: consent for therapeutic and forensic intervention

Consent to Treatment, 2011, p.205-206

1, 2011

Volltextzugriff (PDF)

Informed consent

Consent to Treatment, 2011, p.57-70

1, 2011

Volltextzugriff (PDF)

Research and innovative treatment

Consent to Treatment, 2011, p.133-140

1, 2011

Volltextzugriff (PDF)

Accountability

Consent to Treatment, 2011, p.16-26

1, 2011

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(68)

Publikationsform

Sprache

Englisch
(72)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial

Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer

A Multicenter Open-Label Study to Assess the Safety of a New Formulation of BLP25 Liposome Vaccine in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer

Randomized Trial of Amifostine in Locally Advanced Non–Small-Cell Lung Cancer Patients Receiving Chemotherapy and Hyperfractionated Radiation: Radiation Therapy Oncology Group Trial 98-01

The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: Long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801

Phase II Multicenter Study of Induction Chemotherapy Followed by Concurrent Efaproxiral (RSR13) and Thoracic Radiotherapy for Patients With Locally Advanced Non–Small-Cell Lung Cancer

Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy

Oncologists and family physicians. Using a standardized letter to improve communication

Consent to Treatment

Concurrent weekly carboplatin and radiotherapy for nasopharyngeal carcinoma: report of a joint phase II study

PL-4 Phase III study of concurrent chemotherapy and full course radiotherapy (CT/RT) versus CT/RT induction followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): First outcome analysis of North American Intergroup trial 0139 (RTOG 93-09)

Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15)

Consent to Treatment: Medico-Legal Essentials

P3-023: Preliminary results of an escalating dose phase I /II clinical trial of the anti EGFR monoclonal antibody nimotuzumab in combination with external radiotherapy in patients diagnosed with stage IIB, III or IV NSCLC unsuitable for radical therapy

Radiotherapy plus Chemotherapy with or without Surgical Resection for Stage III Non-Small Cell Lung Cancer

In Reply

Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 rtog patients

O-153 Results of a phase II trial of EGF-P64 vaccine in patients with

2147 Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with hyperfractionated radiotherapy with/without chemotherapy: A multivariate analysis of 682 RTOG patients

Capacity

Introduction to consent

Custody: consent for therapeutic and forensic intervention

Informed consent

Research and innovative treatment

Accountability

Suchergebnisse filtern